Back to Search
Start Over
CD105 (Endoglin): A Potential Anticancer Therapeutic Inhibits Mitogenesis and Map Kinase Pathway Activation
- Source :
- Anticancer research. 41(3)
- Publication Year :
- 2021
-
Abstract
- Background: CD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. Materials and Methods: In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. Results: L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. Conclusion: L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression.
- Subjects :
- MAPK/ERK pathway
Cancer Research
Receptor complex
Cell signaling
Angiogenesis
MAP Kinase Signaling System
RS
RC0254
Transforming Growth Factor beta1
Neoplasms
Animals
Humans
Phosphorylation
Extracellular Signal-Regulated MAP Kinases
Cells, Cultured
Cell Proliferation
Neovascularization, Pathologic
Cell growth
Chemistry
Endoglin
General Medicine
Transfection
QP
Rats
Oncology
embryonic structures
Cancer research
Subjects
Details
- ISSN :
- 17917530 and 02507005
- Volume :
- 41
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Anticancer research
- Accession number :
- edsair.doi.dedup.....5fa673e0fda17d398f1f3aed17cb1058